Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Deferred Taxes (2018 - 2023)

Abvc Biopharma (ABVC) has disclosed Deferred Taxes for 6 consecutive years, with $151387.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Deferred Taxes fell 83.11% year-over-year to $151387.0, compared with a TTM value of $1.1 million through Dec 2023, up 23.6%, and an annual FY2023 reading of $115668.0, down 86.62% over the prior year.
  • Deferred Taxes was $151387.0 for Q4 2023 at Abvc Biopharma, up from -$117414.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $1.0 million in Q4 2021 and bottomed at -$235788.0 in Q2 2021.
  • Average Deferred Taxes over 5 years is $78837.8, with a median of -$46381.5 recorded in 2019.
  • Peak annual rise in Deferred Taxes hit 1270.38% in 2021, while the deepest fall reached 357.89% in 2021.
  • Year by year, Deferred Taxes stood at -$28054.0 in 2019, then crashed by 207.99% to -$86404.0 in 2020, then soared by 1270.38% to $1.0 million in 2021, then decreased by 11.39% to $896049.0 in 2022, then tumbled by 83.11% to $151387.0 in 2023.
  • Business Quant data shows Deferred Taxes for ABVC at $151387.0 in Q4 2023, -$117414.0 in Q3 2023, and $896049.0 in Q4 2022.